April 25th 2024
A Q&A with Kirollos Hanna, PharmD, director of pharmacy at Minnesota Oncology, on the current and future landscape of bispecific antibodies in myeloma treatment.
Translating Progress in BCMA-Directed Therapy for Multiple Myeloma into Advances in Patient Care
1.0 Credit / Hematology, Oncology
View More
Enhancing the Safety of Outpatient CAR T-Cell Administration in Relapsed/Refractory Lymphomas Through Pharmacist-Directed Initiatives
1.0 Credit / Hematology, Oncology
View More
Optimizing Safe Use of Antibody-Drug Conjugates in Solid Tumors Through Pharmacist Interventions
1.0 Credit / Oncology
View More
Ushering in a New Era of Targeted Therapies in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Focus on New and Emerging Antibody-Based Regimens
1.0 Credit / Hematology, Oncology
View More
Optimizing Outcomes for Older Patients With Acute Myeloid Leukemia: A Focus on Alternative Induction Regimens and Maintenance Therapy
1.0 Credit / Hematology, Oncology
View More
Continuing the Conversation in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Addressing Operational Challenges and Integrating New and Emerging Antibody-Based Regimens
1.0 Credit / Hematology, Oncology
View More
Treatment Strategies for Chronic Myeloid Leukemia and the Pharmacist’s Impactful Role
1.0 Credit / Hematology, Oncology
View More
Navigating Current and Emerging Treatment Options for Myelofibrosis After Frontline Failure
1.0 Credit / Oncology
View More
Optimizing Treatment of Early-Stage Breast Cancer and the Pharmacist’s Role in Managing Targeted Therapies
1.5 Credits / Oncology
View More
Enhancing Care for Patients With Endometrial Cancer Through Pharmacist Interventions
1.0 Credit / Oncology, Women’s Health
View More
Targeted Therapies for Non-Small Cell Lung Cancer With ROS1 or KRAS Mutations and the Impact of Pharmacists’ Care
1.0 Credit / Oncology, Pulmonology/Respiratory
View More
Investigating Novel Strategies for the Treatment of Metastatic Small Cell Lung Cancer After Frontline Treatment Failure
1.0 Credit / Oncology
View More
Perspectives on Emerging Data for the Use of Immunotherapy in the Treatment of Early-Stage Non-Small Cell Lung Cancer
1.5 Credits / Oncology, Pulmonology/Respiratory
View More
Managed Care Considerations on the Evolving Role of Bispecific Antibodies in Hematologic Malignancies
1.5 Credits / Hematology, Oncology
View More
Clinical Updates and Strategies for Optimizing Use of Bispecific Antibodies in Hematologic Malignancies
1.0 Credit / Oncology
View More
Promoting Adherence in Early-Stage HR+/HER2- Breast Cancer: The Value of Oncology Pharmacists in Preventing Premature Treatment Discontinuation
1.25 Credit(s) / Oncology; Women’s Health
View More
Continuing the Conversation in Myelofibrosis: The Role of Managed Care in Supporting Treatment Goals Through Appropriate Use of Emerging Therapies
1.0 Credits / Hematology, Oncology
View More
Caring for Patients With Chronic Graft-versus-Host Disease: The Important Role of Pharmacists on the Cancer Care Team
1.5 Credits / Hematology, Oncology
View More
New Frontiers in the Treatment of Lower-Risk Myelodysplastic Syndromes and the Role of Oncology Pharmacists
1.5 Credit / Hematology, Oncology
View More
Advances in EGFR Exon 20 Insertion-Positive Non–Small Cell Lung Cancer: A Focus on Specialty Pharmacy Interventions
1.5 Credits / Oncology, Pulmonology/Respiratory
View More
Improving Pharmacists' Knowledge of Endometrial Cancer and Solutions for Equity and Medication Access
1.5 Credits / Endocrinology, Diabetes & Metabolism, Oncology
View More
Clinical Updates in AML Induction and Maintenance Regimens and the Role of the Specialty Pharmacist
1.5 Credit(s) / Hematology, Oncology
View More
Managed Care Approaches to Improve Outcomes in Frontline Therapy for Advanced Renal Cell Carcinoma
1.0 Credit / Oncology
View More
Demystifying the Details of T-Cell Engaging Bispecific Antibodies: Establishing a Foundation for Oncology Pharmacists
2.0 Credits / Oncology
View More
Continuing the Conversation: A Review of Targeted Therapies for Early-Stage Breast Cancer
0.5 Credit / Oncology, Women’s Health
View More
The Impact of Antibody-Drug Conjugates in Bladder Cancer and Gynecologic Malignancies
1.0 Credit / Oncology
View More
Opportunities to Optimize Treatment of Non-Small Cell Lung Cancer and Gastric Cancers With Antibody-Drug Conjugates
1.0 Credit / Oncology
View More
Assessing the Role of Antibody-Drug Conjugates in Breast Cancer Treatment Pathways
1.0 Credit / Oncology
View More
Exploring the Value of Pharmacist-Led Toxicity Management for New and Emerging Antibody-Drug Conjugates Across Solid Tumors
1.25 Credits / Oncology
View More
Improving Patient Outcomes in TNBC: Immunotherapy, PARP, TROP2, Oh My!
2.0 Credits / Oncology
View More
ASCO20 Virtual: Study Assesses COVID-19 Clinical Data, Finds Cancer Mortality Links
May 28th 2020The findings, which were presented virtually in the 2020 ASCO Virtual Scientific Program, included the association between treatment with hydroxychloroquine plus azithromycin and increased risk of death.
Trastuzumab Deruxtecan Granted Breakthrough Designation for HER2-Mutant Metastatic NSCLC
May 19th 2020Officials with the FDA have granted breakthrough therapy designation to trastuzumab deruxtecan (Enhertu, AstraZeneca and Daiichi Sankyo) for the treatment of HER2-mutant metastatic non-small cell lung cancer (NSCLC).
Fam-trastuzumab Deruxtecan-nxki for HER2-Positive Unresectable or Metastatic Breast Cancer
May 13th 2020Fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo) is indicated for treating adults with unresectable or metastatic HER2-positive breast cancer who have received 2 or more prior anti-HER2–based regimens in the setting of metastasis.
Darolutamide for Non-Metastatic Castration-Resistant Prostate Cancer
May 11th 2020In July 2019, the FDA approved darolutamide (Nubeqa, Bayer) for men with prostate cancer that has not spread (ie, nonmetastatic) and no longer responds to medical or surgical treatment that lowers testosterone (ie androgen deprivation therapy).
FDA OKs Niraparib for Frontline Maintenance Treatment of Ovarian Cancer
April 30th 2020Officials with the FDA approved niraparib (Zejula, GlaxoSmithKline), a once-daily, oral monotherapy, for the first-line maintenance treatment of platinum-responsive advanced ovarian cancer regardless of biomarker status.
FDA OKs New Treatment for Advanced or Metastatic HER2-Positive Breast Cancer
April 17th 2020Officials with the FDA today approved tucatinib (Tukysa, Seattle Genetics) in combination with chemotherapy trastuzumab and capecitabine for the treatment of adults with advanced forms of HER2-positive breast cancer.
A Conversation About Cancer Care During COVID-19: Part 2
April 14th 2020In part 2 of our video interview, Robert Brunault, PharmD, a clinical pharmacy specialist in hematology and oncology at Rhode Island Hospital and the Lifespan Cancer Institute, discussed drug shortages, FDA emergency use authorizations, and the biggest concerns for pharmacists.
A Conversation About Cancer Care During COVID-19
April 10th 2020In a video interview with Drug Topics®, Robert Brunault, PharmD, a clinical pharmacy specialist of hematology and oncology at Rhode Island Hospital and Lifespan Cancer Institute, answers questions about how the COVID-19 pandemic affects patients undergoing treatment for cancer.